Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany
Molecular tumor boards roughly double survival in melanoma when their recommendations are actually used, highlighting barriers beyond medical evidence.
This bicenter retrospective analysis of 80 advanced melanoma patients shows that molecular tumor boards generate actionable treatment recommendations in three-quarters of cases, but implementation is blocked in two-thirds of patients—primarily due to early death or regulatory barriers. When MTB recommendations were implemented, PFS and OS approximately doubled, suggesting that earlier MTB integration could meaningfully improve outcomes.
What the study was
- Study design
- Retrospective bicenter analysis (2 German comprehensive cancer centers)
- Population
- Advanced melanoma patients (88.3% stage IV) referred to molecular tumor boards at 2 comprehensive cancer centers Germany; n=80
- Sample size
- 80
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- International Journal of Cancer
Why it surfaced
Identifies actionable gap: late MTB referral limiting real-world implementation of precision oncology recommendations. Survival benefit when MTB recommendations implemented is clinically meaningful (PFS ratio 1.8).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.